Magnetar Financial LLC Has $247,000 Position in Regeneron Pharmaceuticals, Inc. $REGN

Magnetar Financial LLC cut its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 95.9% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 470 shares of the biopharmaceutical company’s stock after selling 11,072 shares during the period. Magnetar Financial LLC’s holdings in Regeneron Pharmaceuticals were worth $247,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Activest Wealth Management increased its position in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares in the last quarter. Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals in the first quarter valued at about $27,000. Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth about $31,000. Finally, Colonial Trust Advisors acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $32,000. 83.31% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts recently issued reports on REGN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday. UBS Group upped their price target on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research report on Tuesday, September 2nd. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research report on Wednesday, October 29th. Finally, Hsbc Global Res upgraded Regeneron Pharmaceuticals to a “strong-buy” rating in a report on Monday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $757.91.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the sale, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. 7.02% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN opened at $784.61 on Thursday. The stock has a market capitalization of $82.46 billion, a price-to-earnings ratio of 18.79, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $800.99. The firm has a fifty day simple moving average of $627.29 and a 200 day simple moving average of $580.60. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the firm posted $12.46 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.